GAMMA Investing LLC Raises Holdings in Encompass Health Co. (NYSE:EHC)

GAMMA Investing LLC boosted its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 12,207.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 239,628 shares of the company's stock after purchasing an additional 237,681 shares during the period. GAMMA Investing LLC owned about 0.24% of Encompass Health worth $24,270,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of EHC. Janney Montgomery Scott LLC grew its position in Encompass Health by 17.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 13,338 shares of the company's stock valued at $1,232,000 after acquiring an additional 1,981 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Encompass Health by 1,019.1% in the fourth quarter. Blue Trust Inc. now owns 1,578 shares of the company's stock valued at $152,000 after purchasing an additional 1,437 shares during the period. Jennison Associates LLC acquired a new position in shares of Encompass Health in the fourth quarter valued at approximately $52,094,000. Trust Point Inc. lifted its holdings in Encompass Health by 34.5% during the 4th quarter. Trust Point Inc. now owns 4,325 shares of the company's stock worth $399,000 after buying an additional 1,109 shares in the last quarter. Finally, abrdn plc acquired a new stake in Encompass Health during the 4th quarter worth approximately $17,846,000. Hedge funds and other institutional investors own 97.25% of the company's stock.

Insider Activity

In other news, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president now owns 79,710 shares in the company, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares in the company, valued at approximately $64,054,817.10. This trade represents a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock valued at $16,034,082 in the last ninety days. 2.10% of the stock is currently owned by company insiders.

Encompass Health Stock Up 0.2%

NYSE:EHC traded up $0.28 during midday trading on Friday, hitting $121.57. 406,135 shares of the company were exchanged, compared to its average volume of 699,364. Encompass Health Co. has a fifty-two week low of $82.74 and a fifty-two week high of $123.13. The company has a market capitalization of $12.25 billion, a PE ratio of 27.26, a price-to-earnings-growth ratio of 2.31 and a beta of 0.89. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The company has a fifty day simple moving average of $111.55 and a 200 day simple moving average of $102.58.

Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 earnings per share. As a group, equities analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be given a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.56%. Encompass Health's dividend payout ratio (DPR) is presently 14.05%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Royal Bank of Canada lifted their target price on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Wall Street Zen upgraded Encompass Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 24th. Truist Financial restated a "buy" rating and set a $135.00 target price (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Finally, KeyCorp increased their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research report on Tuesday, May 27th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $127.00.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.